Blend Therapeuti?cs Appoints Richard Wooster, PhD, as Chief Scientific Officer
![](/46/pdcnewsitem/03/29/19/EmZg8mxEIDwbZOj.png)
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, has appointed pharmaceutical industry veteran Richard Wooster, PhD, as Chief Scientific Officer.
Dr Wooster will be responsible for leading the company’s research and development strategy and clinical operations as its lead drug candidates focused on oncology advance toward clinical development.
"We are extremely pleased that Richard has joined our team to lead the discovery and development of Blend's innovative drug candidates, which in the near term are focused on the treatment of cancer — an area of Richard’s core expertise," said Mark Iwicki, President and Chief Executive Officer of Blend Therapeutics. "His extensive leadership, strategic and technical experience at the highest levels in cancer genetics and pharmaceutical drug discovery and development will be a great asset to the company to drive innovation and our partnering activities. Richard’s impact from the discovery of mutations in BRCA2 and BRAF, passion to develop personalised medicines, and innovation in drug discovery align perfectly with Blend’s objectives.”
Blend is translating its novel, integrated new molecule discovery engine and nanoparticle engineering platform into a pipeline of therapeutics with differentiated properties for oncology and other disease areas.
"I am thrilled to be leading Blend’s research and development at this exciting time in the company’s growth, and I look forward to advancing Blend’s lead compounds to the clinic,” said Richard Wooster, Ph.D, Chief Scientific Officer of Blend Therapeutics. "We have an opportunity to develop innovative and highly targeted therapeutics that can change how cancer and other serious diseases are treated."
Prior to joining Blend, Dr Wooster was Vice President and Head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline. In this role he led the evaluation of the metabolic pathways that are deregulated in cancer, led the PI3K portfolio of inhibitors in Oncology at GSK and was responsible for the clinical evaluation of the novel antimitotic kinase inhibitors to PLK and CENPE. Before this we led the translational medicine group in Oncology at GSK and worked on Tykerb, Mekinist and Tafinlar. During his academic career he discovered the breast cancer susceptibility gene BRCA2, was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and web site. He has more than 100 peer-reviewed articles and papers in scientific journals, including Nature, Nature Genetics and Science. Richard has a First Class BSc in Biochemistry and a PhD in drug metabolizing enzymes both from the University of Dundee, Scotland.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance